Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA

Executive Summary

A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs. 
Advertisement

Related Content

Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda
Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update
Peter Stein Takes Short Path To Director Of US FDA Drug Office
Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests
The Luxturna Model: Spark’s Approach To Retinal Disease Endpoint Embraced In Gene Therapy Guidance
Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel